Design and evaluation of scFv-RTX-A as a novel immunotoxin for breast cancer treatment: an in silico approach

References

• Heydari, N.; Nikbakhsh, N.; Sadeghi, F.; Farnoush, N.; Khafri, S.; Bastami, M.; Parsian, H. Overexpression of Serum MicroRNA-140-3p in Premenopausal Women with Newly Diagnosed Breast Cancer. Gene. 2018, 655, 25–29. DOI: 10.1016/j.gene.2018.02.032.
   PubMed Web of Science ®Google Scholar
• Hadizadeh, M.; Arani, H. Z.; Olya, M. Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival. Iran. Red Crescent Med. J. 2018, 20(1). DOI: 10.5812/ircmj.57931.
   Web of Science ®Google Scholar
• Eliyatkin, N.; Yalcin, E.; Zengel, B.; Aktas, S.; Vardar, E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J. Breast Health. 2015, 11(2), 59–66. DOI: 10.5152/tjbh.2015.1669.
   PubMedGoogle Scholar
• Goleij Z , Mahmoodzadeh Hosseini H , Amin M , Amani J , Behzadi E, et al. In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy, Int J Cancer Manag. 2019 ; 12(2):e83315. doi:10.5812/ijcm.83315.
   Google Scholar
• Ross, J. S.; Slodkowska, E. A.; Symmans, W. F.; Pusztai, L.; Ravdin, P. M.; Hortobagyi, G. N.; The, H. E. R.-2. Receptor and Breast Cancer: Ten Years of Targeted anti–HER-2 Therapy and Personalized Medicine. oncologist. 2009, 14(4), 320–368. DOI: 10.1634/theoncologist.2008-0230.
   PubMed Web of Science ®Google Scholar
• Wolff, A. C.; Hammond, M. E. H.; Hicks, D. G.; Dowsett, M.; McShane, L. M.; Allison, K. H.; Allred, D. C.; Bartlett, J. M. S.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch. Pathol. Lab. Med. 2013, 138(2), 241–256.
   PubMed Web of Science ®Google Scholar
• Asif, H. M.; Sultana, S.; Ahmed, S.; Akhtar, N.; Tariq, M. HER-2 Positive Breast Cancer – A Mini-Review. Asian Pac. J. Cancer Prev. 2016, 17(4), 1609–1615. DOI: 10.7314/APJCP.2016.17.4.1609.
   PubMedGoogle Scholar
• Gutierrez, C.; Schiff, R. HER2: Biology, Detection, and Clinical Implications. Arch. Pathol. Lab. Med. 2011, 135(1), 55–62.
   PubMed Web of Science ®Google Scholar
• Ross, J. S.; Fletcher, J. A.; Bloom, K. J.; Linette, G. P.; Stec, J.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein. Mol. Cell. Proteomics. 2004, 3(4), 379–398.
   PubMed Web of Science ®Google Scholar
• Schechter, A. L.; Stern, D. F.; Vaidyanathan, L.; Decker, S. J.; Drebin, J. A.; Greene, M. I.; Weinberg, R. A. The Neu Oncogene: An erb-B-related Gene Encoding a 185,000-Mr Tumour Antigen. Nature. 1984, 312(5994), 513.
   PubMed Web of Science ®Google Scholar
• Sliwkowski, M. X.;. Ready to Partner. Nat. Struct. Mol. Biol. 2003, 10(3), 158. DOI: 10.1038/nsb0303-158.
   Google Scholar
• Tai, W.; Mahato, R.; Cheng, K. The Role of HER2 in Cancer Therapy and Targeted Drug Delivery. J. Controlled Release. 2010, 146(3), 264–275. DOI: 10.1016/j.jconrel.2010.04.009.
   PubMed Web of Science ®Google Scholar
• Roskoski, J. R.;. The ErbB/HER Family of Protein-tyrosine Kinases and Cancer. Pharmacol. Res. 2014, 79, 34–74. DOI: 10.1016/j.phrs.2013.11.002.
   PubMed Web of Science ®Google Scholar
• JÁF, V.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; González-Barón, M. PI3K/Akt Signalling Pathway and Cancer. Cancer Treat. Rev. 2004, 30(2), 193–204. DOI: 10.1016/j.ctrv.2003.07.007.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. N. Engl. J. Med. 2001, 344(11), 783–792.
   PubMed Web of Science ®Google Scholar
• Liu, Y.; Xu, J.; Choi, H. H.; Han, C.; Fang, Y.; Li, Y.; Van der Jeught, K.; Xu, H.; Zhang, L.; Frieden, M.; et al. Targeting 17q23 Amplicon to Overcome the Resistance to anti-HER2 Therapy in HER2+ Breast Cancer. Nat. Commun. 2018, 9(1), 4718.
   PubMed Web of Science ®Google Scholar
• Gerratana, L.; Bonotto, M.; Bozza, C.; Ongaro, E.; Fanotto, V.; Pelizzari, G.; Puglisi, F. Pertuzumab and Breast Cancer: Another Piece in the anti-HER2 Puzzle. Expert Opin. Biol. Ther. 2017, 17(3), 365–374.
   PubMed Web of Science ®Google Scholar
• Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-positive Human Xenograft Tumor Models. Cancer Res. 2009, 69(24), 9330–9336. DOI: 10.1158/0008-5472.CAN-08-4597.
   PubMed Web of Science ®Google Scholar
• Better, M.; Chang, C. P.; Robinson, R. R.; Horwitz, A. H. Escherichia Coli Secretion of an Active Chimeric Antibody Fragment. Science. 1988, 240(4855), 1041–1043. DOI: 10.1126/science.3285471.
   PubMed Web of Science ®Google Scholar
• Damle, B.; Hollenbaugh, D.; Timoszyk, J.; Tay, L.; Kaul, S. Development of an Immunoassay for BMS-191352, a Single-chain Immunotoxin, and Its Application to Toxicokinetic Studies. J. Immunoassay Immunochem. 1998, 19(2–3), 145–165.
   Web of Science ®Google Scholar
• Chen, H.-X.; He, F.; Sun, Y.; Luo, Y.; Qiu, H.-J.; Zhang, X.-Y.; Sutton, B. J. Generation and Characterization of Chicken-sourced Single-chain Variable Fragments (Scfvs) against Porcine Interferon-gamma (pIFN-γ). J. Immunoassay Immunochem. 2015, 36(1), 27–44.
   PubMedGoogle Scholar
• Ahmad, Z. A.; Yeap, S. K.; Ali, A. M.; Ho, W. Y.; Alitheen, N. B. M.; Hamid, M. scFv Antibody: Principles and Clinical Application. Clin. Dev. Immunol. 2012, 2012, 1–15. DOI: 10.1155/2012/980250.
   Google Scholar
• Whitlow, M.; Filpula, D. Single-chain Fv Proteins and Their Fusion Proteins. Methods. 1991, 2(2), 97–105. DOI: 10.1016/S1046-2023(05)80209-9.
   Google Scholar
• Arnst, K.; Studennikov, A.; Ustinov, V.; Glushkov, A. Isolation, Production, and Characterization of a New Single Chain Anti-idiotypic Antibody against Benzo [A] Pyrene. J. Immunoassay Immunochem. 2017, 38(6), 652–662. DOI: 10.1080/15321819.2017.1384390.
   PubMedGoogle Scholar
• Becker, N.; Benhar, I. Antibody-based Immunotoxins for the Treatment of Cancer. Antibodies. 2012, 1(1), 39–69. DOI: 10.3390/antib1010039.
   Google Scholar
• Fang, J.; Xiao, L.; Joo, K. I.; Liu, Y.; Zhang, C.; Liu, S.; Conti, P. S.; Li, Z.; Wang, P. A Potent Immunotoxin Targeting Fibroblast Activation Protein for Treatment of Breast Cancer in Mice. Int. J. Cancer. 2016, 138(4), 1013–1023.
   PubMed Web of Science ®Google Scholar
• Weigel, K. J.; Shen, L.; Thomas, C. L.; Alber, D.; Drapalik, L.; Schafer, Z. T.; Lee, S. W. Design and Evaluation of a Peptide-based Immunotoxin for Breast Cancer Therapeutics. FEBS Open Bio. 2015, 5(1), 202–208.
   PubMedGoogle Scholar
• Monastyrnaya, M.; Leychenko, E.; Isaeva, M.; Likhatskaya, G.; Zelepuga, E.; Kostina, E.; Trifonov, E.; Nurminski, E.; Kozlovskaya, E. Actinoporins from the Sea Anemones, Tropical Radianthus Macrodactylus and Northern Oulactis Orientalis: Comparative Analysis of Structure–function Relationships. Toxicon. 2010, 56(8), 1299–1314.
   PubMed Web of Science ®Google Scholar
• Fedorov, S.; Dyshlovoy, S.; Monastyrnaya, M.; Shubina, L.; Leychenko, E.; Kozlovskaya, E.; Jin, J.-O.; Kwak, J.-Y.; Bode, A. M.; Dong, Z.; et al. The Anticancer Effects of Actinoporin RTX-A from the Sea Anemone Heteractis Crispa (=radianthus Macrodactylus). Toxicon. 2010, 55(4), 811–817.
   PubMed Web of Science ®Google Scholar
• Ho, C.; Ko, J.; Lue, H.; Lee, C.; Ferlan, I. Effects of Equinatoxin on the Guinea-pig Atrium. Toxicon. 1987, 25(6), 659–664. DOI: 10.1016/0041-0101(87)90112-7.
   PubMed Web of Science ®Google Scholar
• Sket, D.; Drašlar, K.; Ferlan, I.; Lebez, D. Equinatoxin, a Lethal Protein from Actinia equina—II. Pathophysiological Action. Toxicon. 1974, 12(1), 63–68. DOI: 10.1016/0041-0101(74)90100-7.
   PubMed Web of Science ®Google Scholar
• Alegre-Cebollada, J.; Oñaderra, M.; Gavilanes, J.; Del Pozo, A. M. Sea Anemone Actinoporins: The Transition from a Folded Soluble State to a Functionally Active Membrane-bound Oligomeric Pore. Curr. Protein Pept. Sci. 2007, 8(6), 558–572. DOI: 10.2174/138920307783018686.
   PubMed Web of Science ®Google Scholar
• Garnier, J.; Gibrat, J.-F.; Robson, B. [32] GOR Method for Predicting Protein Secondary Structure from Amino Acid Sequence. Methods Enzymol. 1996, Elsevier 266, 540–553.
   PubMed Web of Science ®Google Scholar
• Monastyrnaya, M. M.; Zykova, T. A.; Apalikova, O. V.; Shwets, T. V.; Kozlovskaya, E. P. Biologically Active Polypeptides from the Tropical Sea Anemone Radianthus Macrodactylus. Toxicon. 2002, 40(8), 1197–1217. DOI: 10.1016/S0041-0101(02)00139-3.
   PubMed Web of Science ®Google Scholar
• Turk, T.;. Cytolytic Toxins from Sea Anemones. J. Toxicol. 1991, 10(3), 223–262.
   Web of Science ®Google Scholar
• Avila, A.; Mateo Acosta, C. D.; Lage, A. A Carcinoembryonic Antigen‐directed Immunotoxin Built by Linking A Monoclonal Antibody to A Hemolytic Toxin. Int. J. Cancer. 1989, 43(5), 926–929. DOI: 10.1002/ijc.2910430533.
   PubMed Web of Science ®Google Scholar
• Pederzolli, C.; Belmonte, G.; Serra, M. D.; Macek, P.; Menestrina, G. Biochemical and Cytotoxic Properties of Conjugates of Transferrin with Equinatoxin II, a Cytolysin from a Sea Anemone. Bioconjugate Chem. 1995, 6(2), 166–173. DOI: 10.1021/bc00032a003.
   PubMed Web of Science ®Google Scholar
• Tejuca, M.; Anderluh, G.; Maček, P.; Marcet, R.; Torres, D.; Sarracent, J.; Alvarez, C.; Lanio, M. E.; Serra, M. D.; Menestrina, G.; et al. Antiparasite Activity of Sea-anemone Cytolysins onGiardia Duodenalis and Specific Targeting with anti-Giardia Antibodies. Int. J. Parasitol. 1999, 29(3), 489–498.
   PubMed Web of Science ®Google Scholar
• Amala, S.;. In Silico Analysis and 3D Modeling of ASAH1 Protein in Farber Lipogranulomatosis. Adv. Biotech. 2010, 10(6), 6–8.
   PubMedGoogle Scholar
• Yeo, S. K.; Guan, J. L. Breast Cancer: Multiple Subtypes within a Tumor? Trends Cancer. 2017, 3(11), 753–760. DOI: 10.1016/j.trecan.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Nagini, S.;. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-Cancer Agents Med. Chem. 2017, 17(2), 152–163. DOI: 10.2174/1871520616666160502122724.
   PubMed Web of Science ®Google Scholar
• Nielsen, D. L.; Kumler, I.; Palshof, J. A.; Andersson, M. Efficacy of HER2-targeted Therapy in Metastatic Breast Cancer. Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Breast. 2013, 22(1), 1–12. DOI: 10.1016/j.breast.2012.09.008.
   PubMed Web of Science ®Google Scholar
• Cardoso, F.; Harbeck, N.; Fallowfield, L.; Kyriakides, S.; Senkus, E.; Group, E. G. W. Locally Recurrent or Metastatic Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2012, 23(suppl_7), vii11–vii9. DOI: 10.1093/annonc/mds232.
   PubMedGoogle Scholar
• Alewine, C.; Hassan, R.; Pastan, I. Advances in Anticancer Immunotoxin Therapy. oncologist. 2015, 20(2), 176–185. DOI: 10.1634/theoncologist.2014-0358.
   PubMed Web of Science ®Google Scholar
• Keshtvarz, M.; Salimian, J.; Yaseri, M.; Bathaie, S. Z.; Rezaie, E.; Aliramezani, A.; Norouzbabaei, Z.; Amani, J.; Douraghi, M. Bioinformatic Prediction and Experimental Validation of a PE38-based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells. Immunotherapy. 2017, 9(5), 387–400.
   PubMed Web of Science ®Google Scholar
• Ahmad, Z. A.; Yeap, S. K.; Ali, A. M.; Ho, W. Y.; Alitheen, N. B.; Hamid, M. scFv Antibody: Principles and Clinical Application. Clinic. Develop. Immunol. 2012, 2012, 980250.
   PubMed Web of Science ®Google Scholar
• Saravanakumar, K.; Sahu, S. K.; Kathiresan, K. In-silico Studies on Fungal Metabolites against Breast Cancer Protein (BRCA1). Asian Pac. J. Trop. Biomed. 2012, 1, 3.
   Google Scholar
• Niu LN, Fu TT, Chen ML, Dong YY, Tu JC, Wang ZH, Wang SQ, Zhao X, Hou NX, Chen Q, Wu Q. Prediction of T cell and B cell epitopes of the 22-, 47-, 56-, and 58-kDa proteins of Orientia tsutsugamushi. Asian Pacific Journal of Tropical Biomedicine. 2019 Oct 1;9(10):443.
   Google Scholar
• Pucca, M. B.; Bertolini, T. B.; Barbosa, J. E.; Galina, S. V. R.; Porto, G. S. Therapeutic Monoclonal Antibodies: ScFv Patents as a Marker of a New Class of Potential Biopharmaceuticals. Braz. J. Pharm. Sci. 2011, 47(1), 31–38.
   Web of Science ®Google Scholar
• Mala J, Puthong S, Maekawa H, Kaneko Y, Palaga T, Komolpis K, Sooksai S. Construction and sequencing analysis of scFv antibody fragment derived from monoclonal antibody against norfloxacin (Nor155). Journal of Genetic Engineering and Biotechnology. 2017 Jun 1;15(1):69-76.
   Google Scholar
• Chen, X.; Zaro, J. L.; Shen, W. C. Fusion Protein Linkers: Property, Design and Functionality. Adv. Drug Delivery Rev. 2013, 65(10), 1357–1369. DOI: 10.1016/j.addr.2012.09.039.
   PubMed Web of Science ®Google Scholar
• Reddy Chichili, V. P.; Kumar, V.; Sivaraman, J. Linkers in the Structural Biology of Protein-protein Interactions. Protein Sci. 2013, 22(2), 153–167. DOI: 10.1002/pro.2206.
   PubMed Web of Science ®Google Scholar
• Alvarado-Mesen, J.; Solano-Campos, F.; Canet, L.; Pedrera, L.; Hervis, Y. P.; Soto, C.; Borbón, H.; Lanio, M. E.; Lomonte, B.; Valle, A.; et al. Cloning, Purification and Characterization of Nigrelysin, a Novel Actinoporin from the Sea Anemone Anthopleura Nigrescens. Biochimie. 2019, 156, 206–223. DOI: 10.1016/j.biochi.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Morante, K.; Caaveiro, J. M.; Tanaka, K.; Gonzalez-Manas, J. M.; Tsumoto, K. A Pore-forming Toxin Requires A Specific Residue for Its Activity in Membranes with Particular Physicochemical Properties. J. Biol. Chem. 2015, 290(17), 10850–10861. DOI: 10.1074/jbc.M114.615211.
   PubMed Web of Science ®Google Scholar
• Anderluh, G.; Macek, P. Cytolytic Peptide and Protein Toxins from Sea Anemones (Anthozoa: Actiniaria). Toxicon. 2002, 40(2), 111–124. DOI: 10.1016/S0041-0101(01)00191-X.
   PubMed Web of Science ®Google Scholar
• Sen, T. Z.; Jernigan, R. L.; Garnier, J.; Kloczkowski, A. GOR V Server for Protein Secondary Structure Prediction. Bioinformatics. 2005, 21(11), 2787–2788. DOI: 10.1093/bioinformatics/bti408.
   PubMed Web of Science ®Google Scholar
• Moghadam, Z. M.; Halabian, R.; Sedighian, H.; Behzadi, E.; Amani, J.; Fooladi, A. A. I. Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An in Silico Approach. Iran. J. Pathol. 2019, 14(4), 305. DOI: 10.30699/IJP.2019.101200.2004.
   PubMedGoogle Scholar
• Eraghi, V.; Derakhshandeh, A.; Hosseini, A.; Motamedi-Boroojeni, A. In Silico Design and Expression of a Novel Fusion Protein of HBHA and High Antigenic Region of FAP-P of Mycobacterium Avium Subsp. Paratuberculosis in Pichia Pastoris. Mol. Biol. Res. Commun. 2017, 6(4), 161.
   PubMed Web of Science ®Google Scholar
• Yang, J.; Zhang, Y. Protein Structure and Function Prediction Using I-TASSER. Curr. Protoc. Bioinf. 2015, 52, 5.8.1–5.8.15. DOI: 10.1002/0471250953.bi0508s52.
   PubMedGoogle Scholar
• Yang, J.; Zhang, Y. I-TASSER Server: New Development for Protein Structure and Function Predictions. Nucleic Acids Res. 2015, 43(W1), W174–81. DOI: 10.1093/nar/gkv342.
   PubMed Web of Science ®Google Scholar
• Hofacker, I. L.;. Vienna RNA Secondary Structure Server. Nucleic Acids Res. 2003, 31(13), 3429–3431. DOI: 10.1093/nar/gkg599.
   PubMed Web of Science ®Google Scholar
• Saha, S.; Raghava, G. P. AlgPred: Prediction of Allergenic Proteins and Mapping of IgE Epitopes. Nucleic Acids Res. 2006, 34(WebServer issue), W202–9. DOI: 10.1093/nar/gkl343.
   PubMedGoogle Scholar
• Saadi, M.; Karkhah, A.; Nouri, H. R. Development of a Multi-epitope Peptide Vaccine Inducing Robust T Cell Responses against Brucellosis Using Immunoinformatics Based Approaches. Infect. Genet. Evol. 2017, 51, 227–234. DOI: 10.1016/j.meegid.2017.04.009.
   PubMed Web of Science ®Google Scholar